Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

BACKGROUND: Bevacizumab plus interferon-α2a (IFN) prolongs progression-free survival to >10 months, which is comparable with sunitinib as first-line treatment of metastatic renal cell carcinoma (RCC). The two regimens have different tolerability profiles; therefore, costs for managing adverse eve...

Descripción completa

Detalles Bibliográficos
Autores principales: Mickisch, G, Gore, M, Escudier, B, Procopio, G, Walzer, S, Nuijten, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813739/
https://www.ncbi.nlm.nih.gov/pubmed/19920817
http://dx.doi.org/10.1038/sj.bjc.6605417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813739/
https://www.ncbi.nlm.nih.gov/pubmed/19920817
http://dx.doi.org/10.1038/sj.bjc.6605417

Ejemplares similares